| Type of support |
Approvals 2001-2023 (US$)(17 Sep 2019) |
Commitments 2001-2023 (US$)(17 Sep 2019) |
Disbursements 2000-2019 (US$)(17 Sep 2019) |
% Disbursed(17 Sep 2019) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
|---|
|
| Total |
$451,024,104 |
$490,106,024 |
$445,028,665 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$16,153,500 |
$16,153,500 |
$16,153,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$25,326,846 |
$37,983,766 |
$16,987,251 |
67% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HepB mono (NVS) |
$3,027,132 |
$3,027,132 |
$3,027,132 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$11,229,378 |
$11,229,378 |
$11,229,378 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$2,680,314 |
$3,161,314 |
$2,427,797 |
91% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$1,321,257 |
$1,321,257 |
$1,321,257 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$7,902,492 |
$7,902,492 |
$6,577,277 |
83% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV-Catch-up campaign (NVS) |
$7,940,000 |
$7,940,000 |
$6,168,184 |
78% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV-Catch-up campaign op.costs (OPC) |
$1,239,442 |
$1,239,442 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Follow-up campaign (NVS) |
$1,776,500 |
$1,776,500 |
$1,963,718 |
111% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Follow-up campaign op.costs (OPC) |
$2,908,874 |
$2,908,874 |
$2,908,872 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A (NVS) |
$3,291,890 |
$4,166,390 |
$3,358,705 |
102% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - campaign (NVS) |
$16,988,586 |
$16,988,586 |
$16,988,586 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up campaign (NVS) |
$3,229,188 |
$3,229,188 |
$3,229,188 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up op.costs (OPC) |
$2,660,854 |
$2,660,854 |
$2,660,854 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - operational costs (OPC) |
$16,135,366 |
$16,135,366 |
$16,135,366 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$102,475,856 |
$107,238,356 |
$105,308,557 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$114,340,012 |
$128,117,512 |
$120,354,994 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$46,504,014 |
$53,033,514 |
$46,022,041 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$3,917,159 |
$3,917,159 |
$3,917,159 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Yellow Fever - campaign (NVS) |
$41,000,659 |
$41,000,659 |
$39,314,064 |
96% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YF - Operational costs (OPC) |
$18,974,785 |
$18,974,785 |
$18,974,785 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format